MEAI
5-Methoxy-2-aminoindane (MEAI, 5-MeO-AI, or Chaperon) is a psychoactive small molecule belonging to the aminoindane class with a mechanism of action described by one patent as being mediated by binding to the dopamine D3 receptor.
It was first prepared by Schering AG in 1956. David Nutt and Amanda Feilding filed a patent application for the drug claiming that it gives people a pleasant intoxication as well as prevent binge drinking.